The clinical outcomes of rituximab biosimilar CT-P10 (Truxima) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.

We evaluated real-world effectiveness and safety of CT-P10 (Truxima) compared with originator rituximab in diffuse large B-cell lymphoma (DLBCL) treatment. Before and after the introduction of CT-P10 to our institute (November 2017), 221 newly-diagnosed DLBCL patients received rituximab with standard cyclophosphamide, vincristine, doxorubicin and prednisone. Patients received originator rituximab throughout ( = 95), switched from originator rituximab to CT-P10 ( = 36), or received CT-P10 throughout ( = 90). There were no significant differences between groups in overall response rate (91.6% vs 94.4% vs 96.7%, respectively;  = 0.403) or complete response rate (84.2% vs 77.8% vs 86.7%, respectively;  = 0.467). Kaplan-Meier survival curves also showed no significant differences in progression-free survival and overall survival between groups (log-rank  = 0.794 and  = 0.955, respectively). Safety profiles were comparable between treatment groups. These data support the ability of CT-P10 to successfully replace originator rituximab in DLBCL treatment and, given the lowered financial barrier, to improve the overall prognosis for DLBCL patients.